73 related articles for article (PubMed ID: 35242673)
21. Development and Validation of a Tumor Mutation Burden-Related Immune Prognostic Model for Lower-Grade Glioma.
Yin W; Jiang X; Tan J; Xin Z; Zhou Q; Zhan C; Fu X; Wu Z; Guo Y; Jiang Z; Ren C; Tang G
Front Oncol; 2020; 10():1409. PubMed ID: 32974146
[TBL] [Abstract][Full Text] [Related]
22. Multi-omics analysis of tumor mutation burden combined with immune infiltrates in melanoma.
Jiang F; Wu C; Wang M; Wei K; Zhou G; Wang J
Clin Chim Acta; 2020 Dec; 511():306-318. PubMed ID: 33164879
[TBL] [Abstract][Full Text] [Related]
23. Correlations Between Tumor Mutation Burden and Immunocyte Infiltration and Their Prognostic Value in Colon Cancer.
Zhou Z; Xie X; Wang X; Zhang X; Li W; Sun T; Cai Y; Wu J; Dang C; Zhang H
Front Genet; 2021; 12():623424. PubMed ID: 33664769
[TBL] [Abstract][Full Text] [Related]
24. Identifying
Xiang X; Gao LM; Zhang Y; Zhu Q; Zhao S; Liu W; Ye Y; Tang Y; Zhang W
PeerJ; 2023; 11():e16618. PubMed ID: 38099311
[TBL] [Abstract][Full Text] [Related]
25. The Efficacy of Pyrotinib as a Third- or Higher-Line Treatment in HER2-Positive Metastatic Breast Cancer Patients Exposed to Lapatinib Compared to Lapatinib-Naive Patients: A Real-World Study.
Ouyang DJ; Chen QT; Anwar M; Xie N; Ouyang QC; Fan PZ; Qian LY; Chen GN; Zhou EX; Guo L; Gu XW; Ding BN; Yang XH; Liu LP; Deng C; Xiao Z; Li J; Wang YQ; Zeng S; Wang S; Yi W
Front Pharmacol; 2021; 12():682568. PubMed ID: 34512325
[No Abstract] [Full Text] [Related]
26. Web-Based Survival Analysis Tool Tailored for Medical Research (KMplot): Development and Implementation.
Lánczky A; Győrffy B
J Med Internet Res; 2021 Jul; 23(7):e27633. PubMed ID: 34309564
[TBL] [Abstract][Full Text] [Related]
27. Pyrotinib Treatment in Patients With HER2-positive Metastatic Breast Cancer and Brain Metastasis: Exploratory Final Analysis of Real-World, Multicenter Data.
Anwar M; Chen Q; Ouyang D; Wang S; Xie N; Ouyang Q; Fan P; Qian L; Chen G; Zhou E; Guo L; Gu X; Ding B; Yang X; Liu L; Deng C; Xiao Z; Li J; Wang Y; Zeng S; Hu J; Zhou W; Qiu B; Wang Z; Weng J; Liu M; Li Y; Tang T; Wang J; Zhang H; Dai B; Tang W; Wu T; Xiao M; Li X; Liu H; Li L; Yi W
Clin Cancer Res; 2021 Aug; 27(16):4634-4641. PubMed ID: 34112711
[TBL] [Abstract][Full Text] [Related]
28. Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
Alva AS; Mangat PK; Garrett-Mayer E; Halabi S; Hansra D; Calfa CJ; Khalil MF; Ahn ER; Cannon TL; Crilley P; Fisher JG; Haslem DS; Shrestha S; Antonelli KR; Butler NL; Warren SL; Rygiel AL; Ranasinghe S; Bruinooge SS; Schilsky RL
J Clin Oncol; 2021 Aug; 39(22):2443-2451. PubMed ID: 33844595
[TBL] [Abstract][Full Text] [Related]
29. Gene Expression Signatures of BRCAness and Tumor Inflammation Define Subgroups of Early-Stage Hormone Receptor-Positive Breast Cancer Patients.
Schroth W; Büttner FA; Kandabarau S; Hoppe R; Fritz P; Kumbrink J; Kirchner T; Brauer HA; Ren Y; Henderson D; Madden SF; Sauer G; Fehm T; Wallwiener D; Fasching PA; Mürdter T; Schwab M; Brauch H;
Clin Cancer Res; 2020 Dec; 26(24):6523-6534. PubMed ID: 33008814
[TBL] [Abstract][Full Text] [Related]
30. Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial.
Emens LA; Esteva FJ; Beresford M; Saura C; De Laurentiis M; Kim SB; Im SA; Wang Y; Salgado R; Mani A; Shah J; Lambertini C; Liu H; de Haas SL; Patre M; Loi S
Lancet Oncol; 2020 Oct; 21(10):1283-1295. PubMed ID: 33002436
[TBL] [Abstract][Full Text] [Related]
31. Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial.
Catenacci DVT; Kang YK; Park H; Uronis HE; Lee KW; Ng MCH; Enzinger PC; Park SH; Gold PJ; Lacy J; Hochster HS; Oh SC; Kim YH; Marrone KA; Kelly RJ; Juergens RA; Kim JG; Bendell JC; Alcindor T; Sym SJ; Song EK; Chee CE; Chao Y; Kim S; Lockhart AC; Knutson KL; Yen J; Franovic A; Nordstrom JL; Li D; Wigginton J; Davidson-Moncada JK; Rosales MK; Bang YJ;
Lancet Oncol; 2020 Aug; 21(8):1066-1076. PubMed ID: 32653053
[TBL] [Abstract][Full Text] [Related]
32. Effectiveness and Safety of Pyrotinib, and Association of Biomarker With Progression-Free Survival in Patients With HER2-Positive Metastatic Breast Cancer: A Real-World, Multicentre Analysis.
Chen Q; Ouyang D; Anwar M; Xie N; Wang S; Fan P; Qian L; Chen G; Zhou E; Guo L; Gu X; Ding B; Yang X; Liu L; Deng C; Xiao Z; Li J; Wang Y; Zeng S; Hu J; Zhou W; Qiu B; Wang Z; Weng J; Liu M; Li Y; Tang T; Wang J; Zhang H; Dai B; Tang W; Wu T; Xiao M; Li X; Liu H; Li L; Yi W; Ouyang Q
Front Oncol; 2020; 10():811. PubMed ID: 32528890
[No Abstract] [Full Text] [Related]
33. ImmuCellAI: A Unique Method for Comprehensive T-Cell Subsets Abundance Prediction and its Application in Cancer Immunotherapy.
Miao YR; Zhang Q; Lei Q; Luo M; Xie GY; Wang H; Guo AY
Adv Sci (Weinh); 2020 Apr; 7(7):1902880. PubMed ID: 32274301
[TBL] [Abstract][Full Text] [Related]
34. Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer.
Schrock AB; Ouyang C; Sandhu J; Sokol E; Jin D; Ross JS; Miller VA; Lim D; Amanam I; Chao J; Catenacci D; Cho M; Braiteh F; Klempner SJ; Ali SM; Fakih M
Ann Oncol; 2019 Jul; 30(7):1096-1103. PubMed ID: 31038663
[TBL] [Abstract][Full Text] [Related]
35. Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial.
Loi S; Giobbie-Hurder A; Gombos A; Bachelot T; Hui R; Curigliano G; Campone M; Biganzoli L; Bonnefoi H; Jerusalem G; Bartsch R; Rabaglio-Poretti M; Kammler R; Maibach R; Smyth MJ; Di Leo A; Colleoni M; Viale G; Regan MM; André F;
Lancet Oncol; 2019 Mar; 20(3):371-382. PubMed ID: 30765258
[TBL] [Abstract][Full Text] [Related]
36. Correlate tumor mutation burden with immune signatures in human cancers.
Wang X; Li M
BMC Immunol; 2019 Jan; 20(1):4. PubMed ID: 30634925
[TBL] [Abstract][Full Text] [Related]
37. Tumor mutational burden is a determinant of immune-mediated survival in breast cancer.
Thomas A; Routh ED; Pullikuth A; Jin G; Su J; Chou JW; Hoadley KA; Print C; Knowlton N; Black MA; Demaria S; Wang E; Bedognetti D; Jones WD; Mehta GA; Gatza ML; Perou CM; Page DB; Triozzi P; Miller LD
Oncoimmunology; 2018; 7(10):e1490854. PubMed ID: 30386679
[TBL] [Abstract][Full Text] [Related]
38. Maftools: efficient and comprehensive analysis of somatic variants in cancer.
Mayakonda A; Lin DC; Assenov Y; Plass C; Koeffler HP
Genome Res; 2018 Nov; 28(11):1747-1756. PubMed ID: 30341162
[TBL] [Abstract][Full Text] [Related]
39. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy.
Cristescu R; Mogg R; Ayers M; Albright A; Murphy E; Yearley J; Sher X; Liu XQ; Lu H; Nebozhyn M; Zhang C; Lunceford JK; Joe A; Cheng J; Webber AL; Ibrahim N; Plimack ER; Ott PA; Seiwert TY; Ribas A; McClanahan TK; Tomassini JE; Loboda A; Kaufman D
Science; 2018 Oct; 362(6411):. PubMed ID: 30309915
[TBL] [Abstract][Full Text] [Related]
40. Immune Checkpoint Inhibition Overcomes ADCP-Induced Immunosuppression by Macrophages.
Su S; Zhao J; Xing Y; Zhang X; Liu J; Ouyang Q; Chen J; Su F; Liu Q; Song E
Cell; 2018 Oct; 175(2):442-457.e23. PubMed ID: 30290143
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]